Members
In this section
Thank you, 2026 Industry Roundtable members.
The 好色先生 and the Industry Roundtable collaborate on opportunities to support neurology and serve patients with neurological disease.
$75,000 members
$50,000 members
$25,000 members
- Alnylam Pharmaceuticals, Inc.
- Amneal Specialty, a division of Amneal Pharmaceuticals LLC
- Annexon Biosciences
- AstraZeneca
- Bristol Myers Squibb
- C2N Diagnostics
- Immunovant
- Ionis Pharmaceuticals
- Johnson & Johnson
- Neurocrine Biosciences
- Octapharma
- Praxis Precision Medicines, Inc.
- Roche
- Sandoz
- The Global CEO Initiative on Alzheimer's Disease
- Xenon Pharmaceuticals
$10,000 members
- Avidity Biosciences
- Cognito Therapeutics
- Dianthus Therapeutics
- ITF Therapeutics
- Kyverna Therapeutics
- Stoke Therapeutics
- Vor Biopharma
All grants, sponsorships, and IRT memberships must comply with the AAN’s Principles Governing Academy Relationships with External Sources of Support, the Accreditation Council for Continuing Medical 好色先生 (ACCME) Standards for Commercial Support, and the Council of Medical Specialty Societies’ Code for Interactions with Companies. AAN accepts financial and in-kind support from corporations, foundations, individuals, and other organizations only if such acceptance would not pose a conflict of interest and in no way impair the AAN’s objectivity, influence, priorities, and actions. Support of AAN programs or participation on the IRT does not permit influence over content, nor does it imply AAN approval or endorsement of an organization’s policies or products.